Merck Animal Health and Alopexx develop pneumonia vaccine for foals

Two companies have come together to develop a vaccine for infections in young horses. Alopexx Vaccine and Merck Animal Health have entered into an exclusive global license agreement to create and commercialize its poly-N-acetyl glucosamine (PNAG) vaccine. The treatment is for Rhodococcus equi (R. equi) pneumonia in foals and other infections. "Published data describing the activity of this vaccine in foals indicates it has the potential to prevent a broad range of bacterial, fungal, and...

from A via a.sfakia on Inoreader http://bit.ly/2CBjynM